Literature DB >> 11577118

Vaccination to prevent varicella and shingles.

J Breuer1.   

Abstract

Vaccination of healthy children against varicella using the live attenuated Oka vaccine has been available in Japan and south Korea for several years. In 1996, a programme of universal vaccination of children to prevent varicella was introduced in the USA and other countries, including Canada, Germany, and Sweden, have licensed the vaccine for use in healthy children. This article reviews the origin of the Oka vaccine and the evidence for vaccine safety and efficacy in children and adults. Universal vaccination of children and targeted vaccination of groups at risk of severe varicella are discussed. The possible use of the Oka vaccine to prevent zoster is reviewed, and initiatives to develop new varicella zoster virus vaccines are outlined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577118      PMCID: PMC1731286          DOI: 10.1136/jcp.54.10.743

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  59 in total

1.  Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.

Authors:  C J White; B J Kuter; A Ngai; C S Hildebrand; K L Isganitis; C M Patterson; A Capra; W J Miller; D L Krah; P J Provost
Journal:  Pediatr Infect Dis J       Date:  1992-01       Impact factor: 2.129

2.  Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine.

Authors:  S J Sperber; B V Smith; F G Hayden
Journal:  Antiviral Res       Date:  1992-03       Impact factor: 5.970

Review 3.  Varicella: complications and costs.

Authors:  S R Preblud
Journal:  Pediatrics       Date:  1986-10       Impact factor: 7.124

4.  Varicella vaccine in pregnancy.

Authors:  D S Seidman; D K Stevenson; A M Arvin
Journal:  BMJ       Date:  1996-09-21

5.  Production and quality control of the Oka-strain live varicella vaccine.

Authors:  E D'Hondt; E Berge; G Colinet; M Duchene; J Peetermans
Journal:  Postgrad Med J       Date:  1985       Impact factor: 2.401

6.  Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection.

Authors:  A M Arvin; C M Koropchak; B R Williams; F C Grumet; S K Foung
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

7.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Biologic and biophysical markers of a live varicella vaccine strain (Oka): identification of clinical isolates from vaccine recipients.

Authors:  Y Hayakawa; S Torigoe; K Shiraki; K Yamanishi; M Takahashi
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

9.  Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox.

Authors:  P A Brunell; J Taylor-Wiedeman; C F Geiser; L Frierson; E Lydick
Journal:  Pediatrics       Date:  1986-01       Impact factor: 7.124

10.  A benefit-cost analysis of a childhood varicella vaccination programme.

Authors:  S R Preblud; W A Orenstein; J P Koplan; K J Bart; A R Hinman
Journal:  Postgrad Med J       Date:  1985       Impact factor: 2.401

View more
  12 in total

1.  Vaccination to prevent varicella and shingles.

Authors:  S J Katona
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

2.  [Therapy of herpes zoster].

Authors:  A J Ullmann
Journal:  Internist (Berl)       Date:  2008-07       Impact factor: 0.743

Review 3.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

Review 4.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

5.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

6.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 7.  Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2015-12-09

Review 8.  Evaluation of efficacy and effectiveness of live attenuated zoster vaccine.

Authors:  G Gabutti; N Valente; N Sulcaj; A Stefanati
Journal:  J Prev Med Hyg       Date:  2014-12

9.  The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

10.  Prevention of shingles: safety and efficacy of live zoster vaccine.

Authors:  Dianna Quan; Randall J Cohrs; Ravi Mahalingam; Donald H Gilden
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.